ERBB2 and breast cancer: Hormone receptor (HR)-positive BC, which expresses ER and/or PgR, is sensitive to anti-estrogen treatment [6] and HER2 overexpression is a predictive marker of HER2-targeted treatment in HER2-positive breast cancer [7].